Divarasib (GDC-6036) Clinical Trials

·Genentech / Roche

Divarasib (GDC-6036) is an oral, once-daily, covalent KRAS G12C inhibitor developed by Genentech/Roche with a selectivity and potency profile designed to improve on first-generation agents. Phase 1 single-agent data in KRAS G12C–mutant NSCLC showed a confirmed response rate of approximately 53% and median progression-free survival of 13.8 months — among the strongest single-agent results in the class. The Krascendo-170 Lung Phase 2/3 study evaluates divarasib plus pembrolizumab and platinum-based chemotherapy in treatment-naive advanced NSCLC; additional trials study combination with anti-EGFR therapy in KRAS G12C–mutant colorectal cancer. Eligibility requires confirmed KRAS G12C mutation and typically specifies prior treatment history.

Check your eligibility

Cancer types studied

Divarasib is under active investigation across multiple tumor types.

Lung Cancer — Non-Small Cell (NSCLC)Colorectal Cancer (CRC)Pancreatic Cancer (PDAC)

How OncoMatch helps you find Divarasib trials

AI reads the protocol

OncoMatch reads the eligibility criteria for every Divarasib trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.

Enter your results

Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.

See your matches

Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.

Find Divarasib trials →